WallStSmart

ConocoPhillips (COP)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 11% more annual revenue ($65.77B vs $59.38B). MRK leads profitability with a 13.6% profit margin vs 12.3%. COP appears more attractively valued with a PEG of 1.14. COP earns a higher WallStSmart Score of 56/100 (C).

COP

Buy

56

out of 100

Grade: C

Growth: 2.0Profit: 6.5Value: 4.7Quality: 5.0

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 3.3Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

COPSignificantly Overvalued (-50.4%)

Margin of Safety

-50.4%

Fair Value

$73.94

Current Price

$113.87

$39.93 premium

UndervaluedFair: $73.94Overvalued
MRKOvervalued (-14.9%)

Margin of Safety

-14.9%

Fair Value

$97.76

Current Price

$111.38

$13.62 premium

UndervaluedFair: $97.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COP4 strengths · Avg: 8.3/10
Market CapQuality
$139.96B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.1%8/10

Strong operational efficiency at 22.1%

Free Cash FlowQuality
$1.35B8/10

Generating 1.3B in free cash flow

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$277.36B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

COP2 concerns · Avg: 2.0/10
Revenue GrowthGrowth
-5.3%2/10

Revenue declined 5.3%

EPS GrowthGrowth
-20.2%2/10

Earnings declined 20.2%

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
5.282/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : COP

The strongest argument for COP centers on Market Cap, Price/Book, Operating Margin. PEG of 1.14 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : COP

The primary concerns for COP are Revenue Growth, EPS Growth.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

COP profiles as a declining stock while MRK is a value play — different risk/reward profiles.

MRK carries more volatility with a beta of 0.20 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

COP scores higher overall (56/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ConocoPhillips

ENERGY · OIL & GAS E&P · USA

ConocoPhillips is an American multinational corporation engaged in hydrocarbon exploration. It is based in the Energy Corridor district of Houston, Texas.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?